[
    [
        {
            "time": "",
            "original_text": "企业观 | 全面布局细胞及基因治疗，高瓴减持凯莱英加大投注新技术领域CXO公司 减持股份",
            "features": {
                "keywords": [
                    "高瓴",
                    "减持",
                    "凯莱英",
                    "细胞及基因治疗",
                    "CXO"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "企业观 | 全面布局细胞及基因治疗，高瓴减持凯莱英加大投注新技术领域CXO公司 减持股份",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "干货！2021年中国医药制造外包(CMO)行业龙头企业发展分析——药明康德：CMO行业的“侵略者”",
            "features": {
                "keywords": [
                    "药明康德",
                    "CMO",
                    "龙头",
                    "医药制造外包"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "外包服务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "干货！2021年中国医药制造外包(CMO)行业龙头企业发展分析——药明康德：CMO行业的“侵略者”",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 9,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "领跑CDMO赛道却遭高瓴减持 凯莱英赴港二次上市有何玄机？",
            "features": {
                "keywords": [
                    "凯莱英",
                    "CDMO",
                    "高瓴",
                    "减持",
                    "赴港上市"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "领跑CDMO赛道却遭高瓴减持 凯莱英赴港二次上市有何玄机？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中信建投医药大健康团队最新研究",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药",
                    "大健康",
                    "研究"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "大健康"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中信建投医药大健康团队最新研究",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]